It has outperformed by 2.22% the S&P500.
Gilead Sciences Inc. (GILD)'s mean Altman Z-Score: 3.70 during the last 7 years. Seabridge Investment Advisors Llc sold 12,802 shares as Gilead Sciences Inc. The Solaris Asset Management Llc holds 850 shares with $60,000 value, down from 25,867 last quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company's stock worth $112,000 after purchasing an additional 144 shares during the last quarter. About 247,815 shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has noticeable measure of stock volatility, for this average true range is an exponential moving average (14 trading days) of the True Ranges. It has underperformed by 16.70% the S&P500.
Macquarie Group Ltd increased Applied Indl Technologies In (NYSE:AIT) stake by 42,769 shares to 558,691 valued at $32.99 million in 2017Q2. It also increased its holding in Neophotonics Corporation (NYSE:NPTN) by 307,900 shares in the quarter, for a total of 2.27M shares, and has risen its stake in Clearside Biomedical Inc. Gilead Sciences had 105 analyst reports since July 29, 2015 according to SRatingsIntel. EPS ratio determined by looking at last 12 month figures is 8.79. GILD's profit will be $2.18 billion for 10.89 P/E if the $1.67 EPS becomes a reality.
Investors sentiment increased to 1.02 in 2017 Q2. Its up 0.02, from 0.91 in 2017Q1. 74 funds opened positions while 270 raised stakes. The shares were sold at an average price of $79.00, for a total value of $3,950,000.00. Stelliam Invest Mgmt LP has invested 1.32% in UnitedHealth Group Inc (NYSE:UNH). Its up 4.99% from 88,200 shares previously. Sg Americas Secs Ltd Liability Company owns 37,492 shares. (NASDAQ:GILD). Private Trust Na holds 0.07% or 4,611 shares in its portfolio. Commercial Bank reported 9,290 shares. Following the completion of the sale, the insider now directly owns 3,231,096 shares in the company, valued at $250,829,982.48. Hussman Strategic accumulated 0.39% or 25,000 shares. Zeke Advisors Limited Liability has 9,242 shares for 0.13% of their portfolio. Benjamin F Edwards & Communications holds 28,804 shares. Salem Investment Counselors has 0% invested in Prudential Financial Inc (NYSE:PRU). Following the transaction, the executive vice president now owns 113,237 shares of the company's stock, valued at approximately $8,945,723.
Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 75% are positive. Prudential Financial had 41 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Bank of America on Wednesday, October 4 with "Neutral". Wells Fargo maintained the shares of PRU in report on Wednesday, August 2 with "Hold" rating. The firm has "Buy" rating given on Tuesday, November 8 by Mizuho. A 5 analysts rate it as either a buy or a strong buy, while 2 believe that investors should either steer clear of (NYSE:JBL) or, if they already own its stock, sell it. The company was upgraded on Thursday, November 5 by Piper Jaffray. Goldman Sachs upgraded Prudential Financial Inc (NYSE:PRU) on Friday, September 23 to "Buy" rating.
The latest exchange of 2.19 Million shares is above its average trading activity of 2.13 Million shares. Alton Gregg H sold 5,000 shares worth $325,114. The stock decreased 2.53% or $1.4 during the last trading session, reaching $53.85. Investors of record on Friday, December 15th will be given a $0.52 dividend. Its up 0.02, from 0.91 in 2017Q1.
Want to see what other hedge funds are holding GILD? It last reported revenues of $276.34 million and EPS of $0.11 for the September 2017, representing -13% top-line growth and 0.26 EPS growth.
A statistical measure of the dispersion of returns (volatility) for RGSE producing salvation in Investors mouth, it has week volatility of 9.84% and for the month booked as 10.99%. Finally, Northern Trust Corp raised its stake in Gilead Sciences by 0.7% in the second quarter. (NASDAQ:GILD) for 48,210 shares.
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. (NASDAQ:GILD). 66,890 were accumulated by Kempner Mngmt. Essex Fincl Svcs Incorporated has invested 0.33% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on February, 6. Meritage Portfolio Management holds 0.08% or 11,173 shares in its portfolio. Shares of JBL have sank -3.41% in the past three monthswhile the S&P 500 has dropped -7.43% in that time. Terril Brothers holds 0.22% in Gilead Sciences, Inc. (NASDAQ:GILD) for 8,305 shares. The volume of 7.7 Million shares climbed down over an trading activity of 9.39 Million shares. Select Sector Spdr Tr (XLK) was reduced too. Finally, Morgan Stanley reiterated an "equal weight" rating and set a $83.00 price objective (up from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. Jefferies reinitiated the stock with "Hold" rating in Tuesday, July 11 report. (NASDAQ:GILD) on Thursday, August 31 with "Buy" rating. As per Tuesday, December 13, the company rating was downgraded by Keefe Bruyette & Woods. The firm has "Buy" rating by Robert W. Baird given on Monday, October 16.